NCT01445535 2021-11-03
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Peking University
Nanfang Hospital, Southern Medical University